SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Derivatives -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (144)4/26/1999 8:31:00 PM
From: Miljenko Zuanic  Respond to of 555
 
I guess not, near term.
It is related to FDA ruling deadline (4-28) on Natrecor NDA.

Miljenko



To: LLCF who wrote (144)4/26/1999 9:26:00 PM
From: sim1  Read Replies (1) | Respond to of 555
 
Brief mention of Scios (among others) in May 3 issue of Forbes.

"Heart Disease: Congestive heart failure.

Drug: Natrecor, a genetically engineered form of the hormone the body uses to bolster a failing heart.

Maker: Scios Inc.

U.S market: 400,000 new cases of congestive heart failure a year; common cause of hospitalization of the elderly.

Status: Nearing FDA approval.

Competitors: 18 other drugs in human trials."


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News